REGN7999, REGN7999 clinical trials

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING DOSES OF REGN7999, A TMPRSS6 ANTAGONIST, IN HEALTHY ADULT SUBJECTS

This early-stage study is testing a new medicine called REGN7999 in healthy people. We want to see if it's safe, how the body handles it, and if it could help with conditions where people have too much iron.